Pfizer CEO: 99 percent chance Delta-specific vaccine won't be necessary

Right now it doesn't seem like a Delta variant-specific COVID-19 vaccine will be necessary because the original shot is holding up well, Pfizer CEO Albert Bourla said Tuesday during an interview with The Atlantic.
However, he added that the company will continue to tweak its vaccine to stay ahead of the curve in case things change. "We are in the middle of the process of producing a specific for Delta variant vaccine," he said. "It is 99.9 percent [probable] that we will not need it."
Bourla's confidence in the current vaccine seems to line up with other experts, who don't expect to be seeing a vaccine tailored to Delta anytime soon, even for potential first doses for people who remain unvaccinated. Vox's Sigal Samuel explored the question in a report published Monday, revealing that infectious disease specialists and virologists don't believe the updated vaccines will be needed and could even lead to manufacturing mixups if they're mass-produced. Plus, the regulatory process would simply take up time "that right now we don't have," said Angela Rasmussen, a virologist at the University of Saskatchewan.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Still, there's agreement that tinkering with the mRNA technology, which can be updated and produced more quickly, will come in handy, especially in the long run because it allows researchers to identify potential hiccups in the process. At the end of the day, it's best to be prepared. Read more at Vox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Art review: Diane Arbus: Constellation
Feature Park Avenue Armory, New York City, through Aug. 17
-
July fiction: Summers to remember
Feature Featuring the latest summer-themed novels from Darrow Farr, Lucas Schaefer, and more
-
Why are flash floods in Texas so deadly?
Today's Big Question Over 100 people, including 27 girls at a summer camp, died in recent flooding
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'